研究者詳細 - 森永　裕士

当院における生体腎移植ドナーの術後フォローアップ状況

山野井友昭, 西村慎吾, 関戸崇了, 吉永香澄, 丸山雄樹, 定平卓也, 別宮謙介, 枝村康平, 小林知子, 小林泰之, 大西康博, 竹内英実, 田邊克幸, 森永裕士, 荒木元朗

日本臨床腎移植学会プログラム・抄録集 57回 208 - 208 2024年2月

当院における先行的生体腎移植の検討

吉永香澄, 関戸崇了, 丸山雄樹, 山野井友昭, 西村慎吾, 富永悠介, 定平卓也, 片山聡, 岩田健宏, 大西康博, 竹内英実, 田邊克幸, 森永裕士, 和田淳, 枝村康平, 小林知子, 小林泰之, 荒木元朗

日本臨床腎移植学会プログラム・抄録集 57回 210 - 210 2024年2月

Late-onset renal variant Fabry disease with R112H mutation and mild increase in plasma globotriaosylsphingosine: a case report. 国際誌

Keiko Tanaka, Hitoshi Sugiyama, Hiroshi Morinaga, Akifumi Onishi, Katsuyuki Tanabe, Haruhito A Uchida, Hiroki Maruyama, Jun Wada

Frontiers in medicine 11 1383309 - 1383309 2024年

記述言語：英語掲載種別：研究論文（学術雑誌）

Fabry disease (FD) is an X-linked disorder resulting in a deficiency of α-galactosidase A (GLA) activity. The R112H mutation of GLA is relatively common in Japanese FD patients, characterized by a late-onset phenotype, almost normal to mild lyso-Gb3 elevation, and mild clinical symptoms, despite low GLA activity. This is due to the structural features of the R112H GLA protein. We herein report the case of a 42-year-old male patient with late-onset FD with a R112H mutation. The patient exhibited only renal involvement with no other organ damage and was successfully treated with galactosidase beta and subsequent migalastat for approximately 10 years. Especially, migalastat was clinically effective in normalizing plasma lyso-Gb3 levels and inhibiting the progression of renal damage associated with FD. Therefore, the use of migalastat in the FD patients with R112H mutation is highly recommended based on this case report.

DOI： 10.3389/fmed.2024.1383309

免疫学的ハイリスク腎移植における低用量リツキシマブを用いた脱感作療法とサイトメガロウイルス感染症 5年間の追跡調査

Behcet病の経過中にIgA腎症を合併し,ステロイド療法とコルヒチン併用により蛋白尿の大幅な改善を認めた一例

浅川知彦, 内田治仁, 片山祐, 田中景子, 竹内英実, 辻憲二, 梅林亮子, 田邊克幸, 森永裕士, 和田淳

日本腎臓学会誌 65 ( 6-W ) 755 - 755 2023年9月

吉永香澄, 関戸崇了, 丸山雄樹, 山野井友昭, 西村慎吾, 大西康博, 竹内英実, 田邊克幸, 森永裕士, 枝村康平, 小林知子, 小林泰之, 和田淳, 荒木元朗

移植 58 ( 総会臨時 ) 307 - 307 2023年9月

Effects of Agalsidase Alfa Enzyme Replacement Therapy on Left Ventricular Hypertrophy on Electrocardiogram in a Female Patient with Fabry Disease

Kazufumi Nakamura, Hiroshi Morita, Yoichi Takaya, Yukihiro Saito, Toru Miyoshi, Hiroshi Morinaga, Hitoshi Sugiyama, Jun Wada, Hiroshi Ito

International Heart Journal 64 ( 3 ) 502 - 505 2023年5月

Elderly Brothers With Fabry Disease Exhibiting Cardiac and Renal Manifestations

Keiko Tanaka, Hitoshi Sugiyama, Hiroshi Morinaga, Akifumi Onishi, Yuzuki Kano, Hidemi Takeuchi, Kenji Tsuji, Motoki Kubo, Katsuyuki Tanabe, Haruhito A. Uchida, Kazufumi Nakamura, Jun Wada

Annals of Internal Medicine: Clinical Cases 2 ( 5 ) 2023年5月

岡山市CKDネットワーク(OCKD-NET)2の登録時データ解析 OCKD-NET1との比較

日本腎臓学会誌 65 ( 3 ) 268 - 268 2023年5月

岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携12年後の追跡調査

大西康博, 内田治仁, 田中景子, 岡本修吾, 竹内英実, 辻憲二, 田邊克幸, 森永裕士, 喜多村真治, 前島洋平, 太田康介, 丸山啓輔, 大城義之, 森岡茂, 瀧上慶一, 蒲生直幸, 杉山斉, 和田淳

日本腎臓学会誌 65 ( 3 ) 240 - 240 2023年5月

医学生に対する腎セミナー開催についての検討

辻憲二, 岡本修吾, 大西康博, 田中景子, 竹内英実, 田邊克幸, 森永裕士, 内田治仁, 喜多村真治, 和田淳

日本腎臓学会誌 65 ( 3 ) 326 - 326 2023年5月

岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携12年後の追跡調査

日本腎臓学会誌 65 ( 3 ) 240 - 240 2023年5月

医学生に対する腎セミナー開催についての検討

辻憲二, 岡本修吾, 大西康博, 田中景子, 竹内英実, 田邊克幸, 森永裕士, 内田治仁, 喜多村真治, 和田淳

日本腎臓学会誌 65 ( 3 ) 326 - 326 2023年5月

岡山市CKDネットワーク(OCKD-NET)2の登録時データ解析 OCKD-NET1との比較

日本腎臓学会誌 65 ( 3 ) 268 - 268 2023年5月

The Effect of Medical Cooperation in the CKD Patients: 10-Year Multicenter Cohort Study. 国際誌

Yasuhiro Onishi, Haruhito A Uchida, Yohei Maeshima, Yuka Okuyama, Nozomu Otaka, Haruyo Ujike, Keiko Tanaka, Hidemi Takeuchi, Kenji Tsuji, Masashi Kitagawa, Katsuyuki Tanabe, Hiroshi Morinaga, Masaru Kinomura, Shinji Kitamura, Hitoshi Sugiyama, Kosuke Ota, Keisuke Maruyama, Makoto Hiramatsu, Yoshiyuki Oshiro, Shigeru Morioka, Keiichi Takiue, Kazuyoshi Omori, Masaki Fukushima, Naoyuki Gamou, Hiroshi Hirata, Ryosuke Sato, Hirofumi Makino, Jun Wada

Journal of personalized medicine 13 ( 4 ) 2023年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

INTRODUCTION: While chronic kidney disease (CKD) is one of the most important contributors to mortality from non-communicable diseases, the number of nephrologists is limited worldwide. Medical cooperation is a system of cooperation between primary care physicians and nephrological institutions, consisting of nephrologists and multidisciplinary care teams. Although it has been reported that multidisciplinary care teams contribute to the prevention of worsening renal functions and cardiovascular events, there are few studies on the effect of a medical cooperation system. METHODS: We aimed to evaluate the effect of medical cooperation on all-cause mortality and renal prognosis in patients with CKD. One hundred and sixty-eight patients who visited the one hundred and sixty-three clinics and seven general hospitals of Okayama city were recruited between December 2009 and September 2016, and one hundred twenty-three patients were classified into a medical cooperation group. The outcome was defined as the incidence of all-cause mortality, or renal composite outcome (end-stage renal disease or 50% eGFR decline). We evaluated the effects on renal composite outcome and pre-ESRD mortality while incorporating the competing risk for the alternate outcome into a Fine-Gray subdistribution hazard model. RESULTS: The medical cooperation group had more patients with glomerulonephritis (35.0% vs. 2.2%) and less nephrosclerosis (35.0% vs. 64.5%) than the primary care group. Throughout the follow-up period of 5.59 ± 2.78 years, 23 participants (13.7%) died, 41 participants (24.4%) reached 50% decline in eGFR, and 37 participants (22.0%) developed end-stage renal disease (ESRD). All-cause mortality was significantly reduced by medical cooperation (sHR 0.297, 95% CI 0.105-0.835, p = 0.021). However, there was a significant association between medical cooperation and CKD progression (sHR 3.069, 95% CI 1.225-7.687, p = 0.017). CONCLUSION: We evaluated mortality and ESRD using a CKD cohort with a long-term observation period and concluded that medical cooperation might be expected to influence the quality of medical care in the patients with CKD.

DOI： 10.3390/jpm13040582

Serum sCD40L and IL-31 in Association with Early Phase of IgA Nephropathy. 国際誌

Keiko Tanaka, Hitoshi Sugiyama, Hiroshi Morinaga, Masashi Kitagawa, Yuzuki Kano, Yasuhiro Onishi, Koki Mise, Katsuyuki Tanabe, Haruhito A Uchida, Jun Wada

Journal of clinical medicine 12 ( 5 ) 2023年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: IgA nephropathy (IgAN) is a major cause of chronic glomerulonephritis worldwide. T cell dysregulation has been reported to contribute to the pathogenesis of IgAN. Methods We measured a broad range of Th1, Th2 and Th17 cytokines in the serum of IgAN patients. We searched for significant cytokines, which were associated with clinical parameters and histological scores in IgAN patients. RESULTS: Among 15 cytokines, the levels of soluble CD40L (sCD40L) and IL-31 were higher in IgAN patients and were significantly associated with a higher estimated glomerular filtration rate (eGFR), a lower urinary protein to creatinine ratio (UPCR), and milder tubulointerstitial lesions (i.e., the early phase of IgAN). Multivariate analysis revealed that serum sCD40L was an independent determinant of a lower UPCR after adjustment for age, eGFR, and mean blood pressure (MBP). CD40, a receptor of sCD40L, has been reported to be upregulated on mesangial cells in IgAN. The sCD40L/CD40 interaction may directly induce inflammation in mesangial areas and may therefore be involved in the development of IgAN. CONCLUSIONS: The present study demonstrated the significance of serum sCD40L and IL-31 in the early phase of IgAN. Serum sCD40L may be a marker of the beginning of inflammation in IgAN.

DOI： 10.3390/jcm12052023

当院における腎移植後コロナウイルス感染症の臨床経過

吉永香澄, 関戸崇了, 丸山雄樹, 山野井友昭, 西村慎吾, 竹内英実, 田邉克幸, 森永裕士, 内田治仁, 和田淳, 枝村康平, 小林知子, 小林泰之, 荒木元朗

移植 57 ( 総会臨時 ) 262 - 262 2022年10月

岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携11年後の追跡調査

大西康博, 内田治仁, 竹内英実, 田中景子, 辻憲二, 田邊克幸, 森永裕士, 木野村賢, 喜多村真治, 前島洋平, 杉山斉, 太田康介, 丸山啓輔, 大城義之, 森岡茂, 瀧上慶一, 蒲生直幸, 和田淳

日本腎臓学会誌 64 ( 3 ) 234 - 234 2022年5月

Presence of decoy cells for 6 months on urine cytology efficiently predicts BK virus nephropathy in renal transplant recipients. 国際誌

Takanori Sekito, Motoo Araki, Kasumi Yoshinaga, Yuki Maruyama, Takuya Sadahira, Shingo Nishimura, Koichiro Wada, Masami Watanabe, Toyohiko Watanabe, Katsuyuki Tanabe, Hidemi Takeuchi, Hiroshi Morinaga, Masashi Kitagawa, Shinji Kitamura, Hitoshi Sugiyama, Jun Wada, Hiroyuki Yanai, Yasutomo Nasu

International journal of urology : official journal of the Japanese Urological Association 28 ( 12 ) 1240 - 1246 2021年12月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVES: To investigate the association between duration of consecutive presence of decoy cells on urine cytology and BK virus nephropathy after kidney transplantation. METHODS: In total, 121 kidney transplant recipients were retrospectively evaluated. The best duration of consecutive presence of decoy cells that could be used to predict BK virus nephropathy was analyzed using the area under the curve for each duration, and recipients were divided into two groups based on the best predictive performance. The effectiveness of SV40 immunostaining on urinary cytology was also analyzed. RESULTS: In total, 2534 urine specimens as well as SV40 immunostaining in 2241 urine specimens were analyzed. Six consecutive months of decoy cell positivity had the best predictive performance for BK virus nephropathy (area under the curve = 0.832). The incidence of BK virus nephropathy in recipients with positive decoy cells for 6 months or more consecutive months (5/44) was significantly higher than in those who had positive decoy cells for less than 6 months (0/77; P = 0.005). Decoy cell positivity had a sensitivity, specificity, positive predictive value, and negative predictive value for BK virus nephropathy of 100%, 66%, 11%, and 100% respectively. SV40 immunostaining provided slightly better specificity (68%) and positive predictive value (12%). CONCLUSIONS: The detection of decoy cells at 6 months or more on urine cytology had high predictive value for BK virus nephropathy in kidney transplant recipients. SV40 immunostaining on urine cytology added minimal diagnostic accuracy.

DOI： 10.1111/iju.14679

Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms. 査読国際誌

Shogo Watari, Motoo Araki, Jun Matsumoto, Kasumi Yoshinaga, Takanori Sekito, Yuki Maruyama, Yosuke Mitsui, Takuya Sadahira, Risa Kubota, Shingo Nishimura, Koichiro Wada, Yasuyuki Kobayashi, Hidemi Takeuchi, Katsuyuki Tanabe, Masashi Kitagawa, Hiroshi Morinaga, Shinji Kitamura, Hitoshi Sugiyama, Noritaka Ariyoshi, Jun Wada, Masami Watanabe, Toyohiko Watanabe, Yasutomo Nasu

Drug metabolism and pharmacokinetics 40 100407 - 100407 2021年10月

記述言語：英語掲載種別：研究論文（学術雑誌）

We evaluated the impact of vonoprazan on blood concentrations of tacrolimus via a retrospective analysis of 52 renal transplant recipients who took tacrolimus and converted from rabeprazole to vonoprazan between August 2018 and September 2019. We compared tacrolimus trough levels upon conversion among groups that were classified based on cytochrome P450 (CYP) gene polymorphisms. CYP3A5 groups were heterozygous or homozygous for CYP3A5∗1 and CYP3A5∗3 alleles. CYP2C19 genotypes were classified as extensive (∗1/∗1), intermediate (∗1/∗2 and ∗1/∗3) or poor metabolizers (∗2/∗2, ∗2/∗3 and ∗3/∗3). Tacrolimus trough levels increased only 0.3 ng/mL upon conversion in the CYP3A5∗3/∗3 group: 5.8 [3.4-7.2] vs 6.1 [3.8-7.9]; p = 0.06. No statistically significance changes in tacrolimus levels also occurred in the CYP3A5∗1/∗1 or CYP3A5∗1/∗3 groups. Subgroup analyses of CYP3A5∗3/∗3 demonstrated low changes for all three CYP2C19 subgroups: 5.2 [4.3-6.5] vs 6.2 [4.3-7.9]; p = 0.07, 6.1 [3.4-7.2] vs 6.7 [4.6-7.9]; p = 0.12 and 5.4 [3.6-6.5] vs 4.7 [3.8-6.3]; p = 1.00, respectively. Conversion to vonoprazan thus resulted in little increase of tacrolimus trough levels, even in the group predicted to be most susceptible (CYP3A5∗3/∗3 and 2C19∗1/∗1), thus supporting the safety of concomitant use of vonoprazan with tacrolimus.

DOI： 10.1016/j.dmpk.2021.100407

超高齢者(oldest-old)における腎代替療法選択を行った2例

大西康博, 内田治仁, 大高望, 竹内英実, 森永裕士, 杉山斉, 吉田賢司, 和田淳

日本老年医学会雑誌 58 ( 4 ) 657 - 657 2021年10月

ABO Blood Incompatibility Positively Affects Early Graft Function: Single-Center Retrospective Cohort Study 国際誌

Shogo Watari, Motoo Araki, Koichiro Wada, Kasumi Yoshinaga, Yuki Maruyama, Yosuke Mitsui, Takuya Sadahira, Risa Kubota, Shingo Nishimura, Yasuyuki Kobayashi, Hidemi Takeuchi, Katsuyuki Tanabe, Masashi Kitagawa, Hiroshi Morinaga, Shinji Kitamura, Hitoshi Sugiyama, Jun Wada, Masami Watanabe, Toyohiko Watanabe, Yasutomo Nasu

Transplantation Proceedings 53 ( 5 ) 1494 - 1500 2021年6月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Elsevier BV

BACKGROUND: We investigated the association between ABO-incompatible (ABO-I) kidney transplantation and early graft function. METHODS: We retrospectively analyzed 95 patients who underwent living donor kidney transplantation between May 2009 and July 2019. It included 61 ABO-compatible (ABO-C) and 34 ABO-I transplantations. We extracted data on immunologic profile, sex, age, cold ischemic time, type of immunosuppression, and graft function. Two definitions were used for slow graft function (SGF) as follows: postoperative day (POD) 3 serum creatinine level >3 mg/dL and estimated glomerular filtration rate (eGFR) <20 mL/min/1.73 m2. Logistic regression analysis was performed to analyze the effect of ABO-I on the incidence of SGF. RESULTS: The characteristics between the ABO-C and ABO-I were not different. ABO-I received rituximab and plasma exchange. Patients also received tacrolimus and mycophenolate mofetil for 2 weeks and prednisolone for 1 week before transplantation as preconditioning. Of the 95 study patients, 19 (20%) and 21 (22%) were identified with SGF according to POD 3 serum creatinine level or eGFR, respectively. Multivariable analysis revealed that ABO-I significantly reduced the incidence of SGF (odds ratio, 0.15; 95% confidence interval, 0.03-0.7; P = .02), and cold ischemic time >150 min increased the incidence of SGF (odds ratio, 6.5; 95% confidence interval, 1.7-25; P = .006). Similar results were identified in POD 3 eGFR. Inferior graft function in patients with SGF was identified up to 6 months after transplantation. CONCLUSION: ABO-I reduces the incidence of SGF, which is associated with an inferior graft function up to 6 months.

DOI： 10.1016/j.transproceed.2021.03.043

岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携10年後の追跡調査

大西康博, 内田治仁, 大高望, 竹内英実, 辻憲二, 田邊克幸, 森永裕士, 木野村賢, 喜多村真治, 前島洋平, 杉山斉, 太田康介, 丸山啓輔, 大城義之, 森岡茂, 瀧上慶一, 蒲生直幸, 和田淳

日本腎臓学会誌 63 ( 4 ) 513 - 513 2021年6月

【自己免疫疾患と腎臓－診断と治療の進歩－】抗糸球体基底膜病（抗GBM病）

森永裕士, 杉山斉

腎臓内科 13 319 - 324 2021年

【加齢と腎泌尿器医療】加齢に伴う腎疾患疾病構造の変化

森永裕士, 杉山斉

腎と透析 90 993 - 998 2021年

Low-dose rituximab induction therapy is effective in immunological high-risk renal transplantation without increasing cytomegalovirus infection. 査読国際誌

Kasumi Yoshinaga, Motoo Araki, Koichiro Wada, Yuki Maruyama, Yosuke Mitsui, Takuya Sadahira, Risa Kubota, Shingo Nishimura, Yasuyuki Kobayashi, Hidemi Takeuchi, Katsuyuki Tanabe, Masashi Kitagawa, Hiroshi Morinaga, Haruhito Adam Uchida, Shinji Kitamura, Hitoshi Sugiyama, Jun Wada, Masami Watanabe, Toyohiko Watanabe, Yasutomo Nasu

International journal of urology : official journal of the Japanese Urological Association 27 ( 12 ) 1136 - 1142 2020年12月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVES: To analyze the effect and impact of low-dose rituximab induction therapy on cytomegalovirus infection in living-donor renal transplantation. METHODS: A total of 92 recipients undergoing living-donor renal transplantation at Okayama University Hospital from May 2009 to August 2018 were evaluated retrospectively. Indications for preoperative rituximab (200 mg/body) were the following: (i) ABO major mismatch; (ii) ABO minor mismatch; (iii) donor-specific anti-human leukocyte antigen antibody-positive; and (iv) focal segmental glomerulosclerosis. We excluded four recipients who were followed <3 months, five who received >200 mg/body rituximab and seven who received prophylactic therapy for cytomegalovirus. RESULTS: There were 59 patients in the rituximab group and 17 in the non-rituximab group. Groups differed significantly in age (median age 53 vs 37 years, respectively; P = 0.04), but not in sex (male 64% vs 65%, P = 1.00), focal segmental glomerulosclerosis (3% vs 0%, P = 1.00) or percentage of cytomegalovirus-seronegative recipients of renal allografts from cytomegalovirus-seropositive donors (12% vs 18%, P = 0.68). The estimated glomerular filtration rate did not differ significantly between groups until 24 months after transplantation. Cytomegalovirus clinical symptoms (10% vs 24%, P = 0.22), including fever ≥38°C (5% vs 12%, P = 0.31) and gastrointestinal symptoms (5% vs 12%, P = 0.31), and the 5-year survival rates of death-censored graft loss (90% vs 83%, P = 0.43) did not differ significantly between groups. CONCLUSIONS: Low-dose rituximab induction therapy is effective in immunological high-risk recipients without increasing cytomegalovirus infection in the absence of valganciclovir prophylaxis.

DOI： 10.1111/iju.14382

Low-dose rituximab induction therapy is effective in immunological high-risk renal transplantation without increasing cytomegalovirus infection.

Yoshinaga K, Araki M, Wada K, Maruyama Y, Mitsui Y, Sadahira T, Kubota R, Nishimura S, Kobayashi Y, Takeuchi H, Tanabe K, Kitagawa M, Morinaga H, Uchida HA, Kitamura S, Sugiyama H, Wada J, Watanabe M, Watanabe T, Nasu Y

Int J Urol 2020年10月

腎不全療法選択説明が緊急透析導入と療法選択に与える影響

森永裕士, 笠原由美子, 井本紀子, 角川紫野, 矢田光子, 大高望, 辻憲二, 北川正史, 田邊克幸, 木野村賢, 喜多村真治, 内田治仁, 杉山斉, 和田淳

日本透析医学会雑誌 53 ( Suppl.1 ) 496 - 496 2020年10月

岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携9年後の追跡調査

大西康博, 内田治仁, 大高望, 辻憲二, 田邊克幸, 森永裕士, 木野村賢, 喜多村真治, 前島洋平, 杉山斉, 太田康介, 丸山啓輔, 大城義之, 森岡茂, 大森一慶, 瀧上慶一, 蒲生直幸, 和田淳

日本腎臓学会誌 62 ( 4 ) 307 - 307 2020年7月

Podocyte autophagy is associated with foot process effacement and proteinuria in patients with minimal change nephrotic syndrome.

Ogawa-Akiyama A, Sugiyama H, Kitagawa M, Tanaka K, Kano Y, Mise K, Otaka N, Tanabe K, Morinaga H, Kinomura M, Uchida HA, Wada J

PLoS One 15 ( 1 ) e0228337 - e0228337 2020年1月

Urine 5MedC, a marker of DNA methylation, in the progression of chronic kidney disease

Onishi A, Sugiyama H, Kitagawa M, Yamanari T, Tanaka K, Ogawa-Akiyama A, Kano Y, Mise K, Tanabe K, Morinaga H, Kinomura M, Uchida HA, Wada J

Dis Markers 2019 5432453 - 5432453 2019年7月

当院で腹膜透析を導入した多発性嚢胞腎患者に関する検討

大西康博, 田邊克幸, 大高望, 大西章史, 北川正史, 森永裕士, 木野村賢, 内田治仁, 杉山斉, 和田淳

日本透析医学会雑誌 52 ( Suppl.1 ) 549 - 549 2019年5月

岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携8年後の追跡調査

大西康博, 内田治仁, 大高望, 田邊克幸, 森永裕士, 木野村賢, 前島洋平, 杉山斉, 太田康介, 丸山啓輔, 平松信, 大城義之, 森岡茂, 福島正樹, 和田淳

日本腎臓学会誌 61 ( 3 ) 388 - 388 2019年5月

Urine 5MedC, a Marker of DNA Methylation, in the Progression of Chronic Kidney Disease. 査読国際誌

Akifumi Onishi, Hitoshi Sugiyama, Masashi Kitagawa, Toshio Yamanari, Keiko Tanaka, Ayu Ogawa-Akiyama, Yuzuki Kano, Koki Mise, Katsuyuki Tanabe, Hiroshi Morinaga, Masaru Kinomura, Haruhito A Uchida, Jun Wada

Disease markers 2019 5432453 - 5432453 2019年

記述言語：英語掲載種別：研究論文（学術雑誌）

Background: Alterations in DNA methylation may be involved in disease progression in patients with chronic kidney disease (CKD). Recent studies have suggested that 5-methyl-2'-deoxycytidine (5MedC) may be a marker of hypermethylation of DNA. Currently, there is no information available regarding the urine levels of 5MedC and its association with the progression of CKD. Method: We examined the urine levels of 5MedC in spot urine samples from 308 patients with CKD (median age: 56 years, male: 53.2%, and glomerulonephritis: 51.0%) using a competitive enzyme-linked immunosorbent assay and investigated the relationships among urine 5MedC, urine albumin, urine α1-microglobulin (α1MG), and the laboratory parameters associated with CKD. The patients were followed for three years to evaluate renal endpoints in a prospective manner. Results: The urine 5MedC level was significantly increased in the later stages of CKD compared to the early to middle stages of CKD. In multiple logistic regression models, urine 5MedC was significantly associated with the prediction of later CKD stages. Urine 5MedC (median value, 65.9 μmol/gCr) was significantly able to predict a 30% decline in the estimated GFR or a development of end-stage renal disease when combined with macroalbuminuria or an increased level of urine α1MG (median value, 5.7 mg/gCr). Conclusion: The present data demonstrate that the urine 5MedC level is associated with a reduced renal function and can serve as a novel and potent biomarker for predicting the renal outcome in CKD patients. Further studies will be necessary to elucidate the role of urine DNA methylation in the progression of CKD.

DOI： 10.1155/2019/5432453

Renal expression of trefoil factor 3 mRNA in association with tubulointerstitial fibrosis in IgA nephropathy. 国際誌

Tanaka K, Sugiyama H, Yamanari T, Mise K, Morinaga H, Kitagawa M, Onishi A, Ogawa-Akiyama A, Tanabe K, Eguchi J, Ohmoto Y, Shikata K, Wada J

Nephrology (Carlton) 23 ( 9 ) 855 - 862 2018年9月

Urine trefoil factors as prognostic biomarkers in chronic Kidney Disease. 国際誌

Yamanari T, Sugiyama H, Tanaka K, Morinaga H, Kitagawa M, Onishi A, Ogawa-Akiyama A, Kano Y, Mise K, Ohmoto Y, Shikata K, Wada J.

Biomed Res Int 2018 3024698 - 3024698 2018年4月

岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携7年後の追跡調査

大西康博, 内田治仁, 大高望, 奥山由加, 田邊克幸, 森永裕士, 木野村賢, 前島洋平, 杉山斉, 太田康介, 平松信, 大城義之, 森岡茂, 福島正樹, 和田淳

日本腎臓学会誌 60 ( 3 ) 399 - 399 2018年4月

Serum cystatin C is an independent biomarker associated with the renal resistive index in patients with chronic kidney disease.

Ogawa-Akiyama A, Sugiyama H, Kitagawa M, Tanaka K, Onishi A, Yamanari T, Morinaga H, Uchida HA, Nakamura K, Ito H, Wada J.

PLoS One 13 ( 3 ) e0193695 - e0193695 2018年3月

Complication of PD (except infection)

Hitoshi Sugiyama, Toshio Yamanari, Hiroshi Morinaga

The Essentials of Clinical Dialysis 257 - 275 2018年1月

Serum cystatin C is an independent biomarker associated with the renal resistive index in patients with chronic kidney disease. 査読国際誌

Ayu Ogawa-Akiyama, Hitoshi Sugiyama, Masashi Kitagawa, Keiko Tanaka, Akifumi Onishi, Toshio Yamanari, Hiroshi Morinaga, Haruhito Adam Uchida, Kazufumi Nakamura, Hiroshi Ito, Jun Wada

PloS one 13 ( 3 ) e0193695 2018年

記述言語：英語掲載種別：研究論文（学術雑誌）

Cystatin C is a cysteine protease inhibitor that is produced by nearly all human cells. The serum level of cystatin C is a stronger predictor of the renal outcome and the risk of cardiovascular events than the creatinine level. The resistive index (RI) on renal Doppler ultrasonography is a good indicator of vascular resistance as well as the renal outcomes in patients with chronic kidney disease (CKD). However, it is unclear whether serum cystatin C is associated with signs of vascular dysfunction, such as the renal RI. We measured the serum cystatin C levels in 101 CKD patients and investigated the relationships between cystatin C and markers of vascular dysfunction, including the renal RI, ankle-brachial pulse wave velocity (baPWV), intima-media thickness (IMT), and cardiac function. The renal RI was significantly correlated with the serum cystatin C level (p < 0.0001, r = 0.6920). The serum cystatin C level was found to be a significant determinant of the renal RI (p < 0.0001), but not the baPWV, in a multivariate regression analysis. The multivariate odds ratio of the serum cystatin C level for a renal RI of more than 0.66 was statistically significant (2.92, p = 0.0106). The area under the receiver-operating characteristic curve comparing the sensitivity and specificity of cystatin C for predicting an RI of more than 0.66 was 0.882 (cutoff value: 2.04 mg/L). In conclusion, the serum cystatin C level is an independent biomarker associated with the renal RI in patients with CKD.

DOI： 10.1371/journal.pone.0193695

Arterial Stiffness is an Independent Risk Factor for Anemia after Percutaneous Native Kidney Biopsy 査読

Keiko Tanaka,Masashi Kitagawa*,Akifumi Onishi*,Toshio Yamanari*,Ayu Ogawa-Akiyama,Koki Mise,Tatsuyuki Inoue,Hiroshi Morinaga*,Haruhito A. Uchida *,Hitoshi Sugiyama*,Jun Wada*

Kidney and Blood Pressure Research, Renal Physiology and Biochemistry, Renal Physiology 42 ( 2 ) 284 - 293 2017年6月

Arterial stiffness is an independent risk factor for anemia after percutaneous native kidney biopsy.

Tanaka K, Kitagawa M, Onishi A, Yamanari T, Ogawa-Akiyama A, Mise K, Inoue T, Morinaga H, Uchida HA, Sugiyama H, Wada J

Kidney Blood Press Res 42 ( 2 ) 284 - 293 2017年4月

baPWVによる動脈硬化評価は腎生検後の貧血進行の予測因子となる

田中景子, 北川正史, 大西章史, 山成俊夫, 秋山愛由, 三瀬広記, 森永裕士, 内田治仁, 杉山斉, 和田淳

日本腎臓学会誌 59 ( 3 ) 345 - 345 2017年4月

腎内細動脈硝子化、動脈硬化病変は全身の動脈硬化指標の異なる因子が規定する

北川正史, 杉山斉, 大西章史, 山成俊夫, 田中景子, 三瀬広記, 森永裕士, 内田治仁, 和田淳

日本腎臓学会誌 59 ( 3 ) 309 - 309 2017年4月

当院における透析導入患者の潜在性結核感染症スクリーニング状況の検討.

加藤綾子、大西章史、杉山斉、森下美智子、宮脇義亜、荒田夕佳、益田加奈、秋山愛由、梅林亮子、山成俊夫、森永裕士、田邊克幸、木野村賢、和田淳

中国腎不全研究会誌 25 67 - 68 2017年3月

Successful treatment with glucocorticoid for secondary Fanconi syndrome caused by sarcoidosis 査読国際誌

Daisuke Omura, Hideharu Hagiya, Yoshihisa Hanayama, Kou Hasegawa, Hiroshi Morinaga, Atsue Kikuta, Hitomi Kataoka, Fumio Otsuka

MODERN RHEUMATOLOGY 27 ( 3 ) 545 - 547 2017年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：SPRINGER

A 77-year-old female with renal dysfunction, hypercalcemia, and hypercalciuria was presented. Systemic investigations including renal biopsy showed that the patient had Fanconi syndrome secondary to renal sarcoidosis. Treatment with 25 mg per day of prednisolone was initiated and her condition improved. Complication of Fanconi syndrome in patients with sarcoidosis is extremely rare. Although the pathological mechanism is still unknown, corticosteroid therapy was effective for ameliorating proteinuria, glycosuria, hypercalciuria, and aminoaciduria.

DOI： 10.3109/14397595.2014.1002163

【高齢者の腹膜透析-assisted PDの現実と可能性】高齢透析患者の生命予後，合併症，QOL，ADLーHDとPD，エビデンスの整理 (1) 生命予後，合併症.

森永裕士

臨牀透析 32 ( 10 ) 1271 - 1276 2016年9月

長期透析患者に対する腎移植症例の検討.

有吉勇一、荒木元朗、光井洋介、吉岡貴史、和田耕一郎、小林泰之、江原伸、渡邉豊彦、那須保友、山下里美、北川正史、田邊克幸、森永裕士、杉山斉、和田淳

日本臨床腎移植学会雑誌 4 ( 1 ) 113 - 117 2016年7月

記述言語：日本語出版者・発行元：(一社)日本臨床腎移植学会

【目的】近年夫婦間移植の増加や献腎移植の待機年数の延長に伴い、長期透析患者に対する腎移植が増加しており、移植前透析期間が腎移植に与える影響を検証した。【方法】2009年から2015年12月までに岡山大学病院泌尿器科で腎移植を施行した59例(生体57例、献腎2例)を対象に透析歴10年以上の症例を長期透析群とし、患者背景、免疫学的リスク、感染症、移植腎機能、手術操作、術後合併症を透析歴10年未満の短期群と比較検討した。【結果】短期群52例、長期群7例で年齢の中央値は短期群42.5歳、長期群62歳で有意な差はなかった(p=0.0959)。長期群は2例(29%)が献腎移植症例でCMV D+R-は短期群12例(23%)のみに認めた。尿管吻合時間は短期群32分、長期群40分であった。術後血清Creは短期群1.34mg/dL、長期群1.17mg/dLでありCMV血症や拒絶反応も両群間で差がなかった。【結論】長期透析患者に対する腎移植では尿管吻合に難渋する症例を認めたが、移植腎機能や合併症は短期群と同等であった。(著者抄録)

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2016&ichushi_jid=J06262&link_issn=&doc_id=20160819430012&doc_link_id=%2Fem0sfcrt%2F2016%2F000401%2F013%2F0113-0117%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fem0sfcrt%2F2016%2F000401%2F013%2F0113-0117%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

血清と尿中TFF3の上昇は、間質性腎炎の線維化と相関する

田中景子, 杉山斉, 山成俊夫, 秋山愛由, 大西章史, 北川正史, 森永裕士, 菊本陽子, 井上達之, 和田淳

日本腎臓学会誌 58 ( 3 ) 259 - 259 2016年5月

非糖尿病慢性腎臓病患者において、FGF21は拡張機能、FGF23は収縮機能と関連する

北川正史, 杉山斉, 井上達之, 森永裕士, 秋山愛由, 山成俊夫, 大西章史, 田中景子, 井上章子, 菊本陽子, 和田淳

日本腎臓学会誌 58 ( 3 ) 274 - 274 2016年5月

効果的なCKD検査教育入院プログラムを考える医療としてのCKD教育入院と糖尿病透析予防指導の効果・意義

和田淳, 木野村賢, 田邊克幸, 森永裕士, 杉山斉, 四方賢一

日本腎臓学会誌 58 ( 3 ) 241 - 241 2016年5月

Epidemiology and clinical significance of nephrosclerosis 査読

Hiroshi Sato,Hitoshi Sugiyama*,Hiroshi Morinaga*,Hitoshi Yokoyama

Japanese Journal of Nephrology, Nippon Jinzo Gakkai shi, The Japanese Journal of Nephrology, Nihon Jinzo Gakkai shi 58 ( 2 ) 76 - 79 2016年1月

【急速進行性糸球体腎炎Update】わが国における腎臓病レジストリーとRPGNのコホート研究

杉山斉, 森永裕士, 佐田憲映, 臼井丈一, 横山仁, 山縣邦弘

医学のあゆみ 257 136 - 140 2016年

【腎硬化症】腎硬化症の疫学・臨床

佐藤博, 杉山斉, 森永裕士, 横山仁

日本腎臓学会誌 58 76 - 79 2016年

IgA腎症における指定難病症例の解析

田中景子, 井上達之, 大西章史, 山成俊夫, 秋山愛由, 北川正史, 森永裕士, 菊本陽子, 杉山斉, 和田淳

日本腎臓学会誌 57 ( 3 ) 464 - 464 2015年4月

血中FGF21は腎機能、蛋白尿と独立した腎予後を予測するバイオマーカーである

北川正史, 杉山斉, 森永裕士, 秋山愛由, 山成俊夫, 大西章史, 田中景子, 菊本陽子, 井上達之, 内田治仁, 和田淳

日本腎臓学会誌 57 ( 3 ) 465 - 465 2015年4月

Autoimmune pancreatitis and minimal change nephrotic syndrome: an unusual association? 査読国際誌

Yuka Okuyama, Haruhito Adam Uchida, Masafumi Tenta, Tomokazu Nunoue, Ryoko Umebayashi, Hiroshi Morinaga, Shinji Kitamura, Yohei Maeshima, Hitoshi Sugiyama, Jun Wada

Nephrology (Carlton, Vic.) 20 ( 3 ) 225 - 6 2015年3月

Autoimmune pancreatitis and minimal change nephrotic syndrome: an unusual association? 査読

Okuyama Y, Uchida HA, Tenta M, Nunoue T, Umebayashi R, Morinaga H, Kitamura S, Maeshima Y, Sugiyama H, Wada J

Nephrology (Carlton) 20 ( 3 ) 225 - 226 2015年3月

当科で施行した生体腎移植レシピエント、ドナーのQOL評価

有吉勇一, 荒木元朗, 宗石理沙, 吉岡貴史, 和田耕一郎, 小林泰之, 佐々木克己, 江原伸, 渡辺豊彦, 那須保友, 公文裕巳, 有森千聖, 北川正史, 田邊克幸, 森永裕士, 菊本陽子, 内田治仁, 喜多村真治, 前島洋平, 杉山斉, 槇野博史

移植 49 ( 4-5 ) 377 - 377 2014年11月

A LOWER LEVEL OF SERUM BETA-2 MICROGLOBULIN SIGNIFICANTLY PREDICTS BETTER SURVIVAL IN ASSOCIATION WITH PRESERVED RESIDUAL RENAL FUNCTION IN PATIENTS ON PERITONEAL DIALYSIS - A PROSPECTIVE MULTICENTER COHORT STUDY (PDR-CS) 査読

Morinaga Hiroshi, Sugiyama Hitoshi, Ito Yasuhiko, Tsuruya Kazuhiko, Yoshida Hisako, Maruyama Hiroki, Goto Shin, Nishino Tomoya, Terawaki Hiroyuki, Nakayama Masaaki, Nakamoto Hidetomo, Matsuo Seiichi, Makino Hirofumi

NEPHROLOGY 19 70 - 70 2014年5月

岡山大学泌尿器科におけるpreemptive腎移植症例の検討

有吉勇一, 荒木元朗, 宗石理沙, 吉岡貴史, 和田耕一郎, 小林泰之, 佐々木克己, 江原伸, 渡辺豊彦, 那須保友, 公文裕巳, 清水千聖, 赤木滋, 森永裕士, 田邊克幸, 北川正史, 杉山斉, 和田淳, 槇野博史

移植 49 ( 1 ) 167 - 167 2014年5月

化学療法中に発生した血液透析を要する急性腎不全症例の検討

田邊克幸, 田中景子, 小松原基志, 大西章史, 寺見直人, 中山和典, 綿谷博雪, 益田加奈, 井上淳子, 山成俊夫, 森永裕士, 杉山斉, 槇野博史

日本透析医学会雑誌 47 ( Suppl.1 ) 1011 - 1011 2014年5月

Sarcoid-like lung granulomas in a hemodialysis patient treated with a dipeptidyl peptidase-4 inhibitor. 査読

Sada KE, Wada J, Morinaga H, Tuchimochi S, Uka M, Makino H

Clin Kidney J 7 ( 2 ) 182 - 185 2014年4月

Sarcoid-like lung granulomas in a hemodialysis patient treated with a dipeptidyl peptidase-4 inhibitor 査読

Ken-Ei Sada, Jun Wada, Hiroshi Morinaga, Shigeyuki Tuchimochi, Mayu Uka, Hirofumi Makino

Clinical Kidney Journal 7 ( 2 ) 182 - 185 2014年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Oxford University Press

It has been reported that the inhibition of dipeptidyl peptidase-4 (DPP-4)/CD26 on T-cells by DPP-4 enzymatic inhibitors suppresses lymphocyte proliferation and reduces the production of various cytokines, including tumor necrosis factor (TNF)-α. A 72-year-old female with diabetic nephropathy on hemodialysis developed multiple lung nodules following the administration of vildagliptin. A biopsy demonstrated the histology of granulomas without caseous necrosis. The discontinuation of vildagliptin resulted in the disappearance of the granulomas within 4 months. As granulomatosis often develops in patients under anti-TNF-α therapy, the accumulation of DPP-4 inhibitors or its metabolites is possibly linked to unrecognized complications, such as sarcoid-like lung granulomas. © 2014 © The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

DOI： 10.1093/ckj/sft172

Scopus

A Decreased Level of Serum Soluble Klotho Is an Independent Biomarker Associated with Arterial Stiffness in Patients with Chronic Kidney Disease 査読

その他リンク： http://orcid.org/0000-0003-1468-5170

急性腎不全で発症し透析を離脱し得たSLEの1例

大西章史, 森永裕士, 赤木滋, 北川正史, 井上章子, 寺見直人, 山成俊夫, 辻憲二, 氏家はる代, 小川愛由, 中山和典, 綿谷博雪, 井上淳子, 田邊克幸, 杉山斉, 槇野博史

日本腎臓学会誌 55 ( 6 ) 1211 - 1211 2013年8月

Kitagawa Masashi, Sugiyama Hitoshi, Morinaga Hiroshi, Inoue Tatsuyuki, Takiue Keiichi, Ogawa Ayu, Yamanari Toshio, Kikumoto Yoko, Uchida Haruhito Adam, Kitamura Shinji, Maeshima Yohei, Nakamura Kazufumi, Ito Hiroshi, Makino Hirofumi

PLoS ONE 8 ( 2 ) e56695 - e56695 2013年2月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Public Library Science

Background: Klotho was originally identified in a mutant mouse strain unable to express the gene that consequently showed shortened life spans. In humans, low serum Klotho levels are related to the prevalence of cardiovascular diseases in community-dwelling adults. However, it is unclear whether the serum Klotho levels are associated with signs of vascular dysfunction such as arterial stiffness, a major determinant of prognosis, in human subjects with chronic kidney disease (CKD). Methods: We determined the levels of serum soluble Klotho in 114 patients with CKD using ELISA and investigated the relationship between the level of Klotho and markers of CKD-mineral and bone disorder (CKD-MBD) and various types of vascular dysfunction, including flow-mediated dilatation, a marker of endothelial dysfunction, ankle-brachial pulse wave velocity (baPWV), a marker of arterial stiffness, intima-media thickness (IMT), a marker of atherosclerosis, and the aortic calcification index (ACI), a marker of vascular calcification. Results: The serum Klotho level significantly correlated with the 1,25-dihydroxyvitamin D level and inversely correlated with the parathyroid hormone level and the fractional excretion of phosphate. There were significant decreases in serum Klotho in patients with arterial stiffness defined as baPWV >= 1400 cm/sec, atherosclerosis defined as maximum IMT >= 1.1 mm and vascular calcification scores of ACI>0%. The serum Klotho level was a significant determinant of arterial stiffness, but not endothelial dysfunction, atherosclerosis or vascular calcification, in the multivariate analysis in either metabolic model, the CKD model or the CKD-MBD model. The adjusted odds ratio of serum Klotho for the baPWV was 0.60 (p = 0.0075). Conclusions: Decreases in the serum soluble Klotho levels are independently associated with signs of vascular dysfunction such as arterial stiffness in patients with CKD. Further research exploring whether therapeutic approaches to maintain or elevate the Klotho level could improve arterial stiffness in CKD patients is warranted.

DOI： 10.1371/journal.pone.0056695

CiNii Article

Effluent Free Radicals Are Associated with Residual Renal Function and Predict Technique Failure in Peritoneal Dialysis Patients 査読

HD併用療法の実態調査〜アンケート集計結果とPDR-CSレジストリから〜

森永裕士, 杉山斉, 山成俊夫, 小川愛由, 北川正史, 瀧上慶一, 菊本陽子, 内田治仁, 喜多村真治, 赤木滋, 前島洋平, 槇野博史

腎と透析別冊腹膜透析2013 75 161 - 162 2013年

【腎疾患治療薬マニュアル2013-14】透析患者に対する薬の使い方疾患別・病態別[感染症] MRSA感染症

森永裕士, 杉山斉

腎と透析 74 ( 増刊 ) 579 - 583 2013年

REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY SYNDROME IN A YOUNG ADULT PATIENT RECEIVING PERITONEAL DIALYSIS 査読

Ayu Ogawa, Hitoshi Sugiyama, Kazunori Nakayama, Hiroshi Morinaga, Shigeru Akagi, Hirofumi Makino

PERITONEAL DIALYSIS INTERNATIONAL 32 ( 6 ) 587 - 589 2012年11月

The frequency of Fabry disease with the E66Q variant in the ?-galactosidase A gene in Japanese dialysis patients: a case report and a literature review 査読

Y. Kikumoto, H. Sugiyama, H. Morinaga, T. Inoue, K. Takiue, M. Kitagawa, D. Saito, Y. Takatori, M. Kinomura, S. Kitamura, S. Akagi, K. Sada, K. Nakao, Y. Maeshima, H. Kitayama, H. Makino

Clinical Nephrology 78 ( 09 ) 224 - 229 2012年9月

Hiroshi Morinaga, Hitoshi Sugiyama, Tatsuyuki Inoue, Keiichi Takiue, Yoko Kikumoto, Masashi Kitagawa, Shigeru Akagi, Kazushi Nakao, Yohei Maeshima, Ikuko Miyazaki, Masato Asanuma, Makoto Hiramatsu, Hirofumi Makino

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 32 ( 4 ) 453 - 461 2012年7月

担当区分：筆頭著者記述言語：英語掲載種別：学位論文（博士）出版者・発行元：SAGE Publications

<sec><title>Objective</title> Residual renal function (RRF) is associated with low oxidative stress in peritoneal dialysis (PD). In the present study, we investigated the relationship between the impact of oxidative stress on RRF and patient outcomes during PD.

</sec><sec><title>Methods</title> Levels of free radicals (FRs) in effluent from the overnight dwell in 45 outpatients were determined by electron spin resonance spectrometry. The FR levels, clinical parameters, and the level of 8-hydroxy-2′-deoxyguanosine were evaluated at study start. The effects of effluent FR level on technique and patient survival were analyzed in a prospective cohort followed for 24 months.

</sec><sec><title>Results</title> Levels of effluent FRs showed significant negative correlations with daily urine volume and residual renal Kt/V, and positive correlations with plasma β₂-microglobulin and effluent 8-hydroxy-2′-deoxyguanosine. A highly significant difference in technique survival ( p < 0.05), but not patient survival, was observed for patients grouped by effluent FR quartile. The effluent FR level was independently associated with technique failure after adjusting for patient age, history of cardiovascular disease, and presence of diabetes mellitus ( p < 0.001). The level of effluent FRs was associated with death-censored technique failure in both univariate ( p < 0.001) and multivariate ( p < 0.01) hazard models. Compared with patients remaining on PD, those withdrawn from the modality had significantly higher levels of effluent FRs ( p < 0.005).

</sec><sec><title>Conclusions</title> Elevated effluent FRs are associated with RRF and technique failure in stable PD patients. These findings highlight the importance of oxidative stress as an unfavorable prognostic factor in PD and emphasize that steps should be taken to minimize oxidative stress in these patients.

</sec>

DOI： 10.3747/pdi.2011.00032

その他リンク： http://journals.sagepub.com/doi/full-xml/10.3747/pdi.2011.00032

Acatalasemic mice are mildly susceptible to adriamycin nephropathy and exhibit increased albuminuria and glomerulosclerosis 査読

Keiichi Takiue, Hitoshi Sugiyama, Tatsuyuki Inoue, Hiroshi Morinaga, Yoko Kikumoto, Masashi Kitagawa, Shinji Kitamura, Yohei Maeshima, Da-Hong Wang, Noriyoshi Masuoka, Keiki Ogino, Hirofumi Makino

BMC NEPHROLOGY 13 14 2012年3月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：BIOMED CENTRAL LTD

Background: Catalase is an important antioxidant enzyme that regulates the level of intracellular hydrogen peroxide and hydroxyl radicals. The effects of catalase deficiency on albuminuria and progressive glomerulosclerosis have not yet been fully elucidated. The adriamycin (ADR) nephropathy model is considered to be an experimental model of focal segmental glomerulosclerosis. A functional catalase deficiency was hypothesized to exacerbate albuminuria and the progression of glomerulosclerosis in this model.
Methods: ADR was intravenously administered to both homozygous acatalasemic mutant mice (C3H/AnLCs(b)Cs(b)) and control wild-type mice (C3H/AnLCs(a)Cs(a)). The functional and morphological alterations of the kidneys, including albuminuria, renal function, podocytic, glomerular and tubulointerstitial injuries, and the activities of catalase were then compared between the two groups up to 8 weeks after disease induction. Moreover, the presence of a mutation of the toll-like receptor 4 (tlr4) gene, which was previously reported in the C3H/HeJ strain, was investigated in both groups.
Results: The ADR-treated mice developed significant albuminuria and glomerulosclerosis, and the degree of these conditions in the ADR-treated acatalasemic mice was higher than that in the wild-type mice. ADR induced progressive renal fibrosis, renal atrophy and lipid peroxide accumulation only in the acatalasemic mice. In addition, the level of catalase activity was significantly lower in the kidneys of the acatalasemic mice than in the wild-type mice during the experimental period. The catalase activity increased after ADR injection in wild-type mice, but the acatalasemic mice did not have the ability to increase their catalase activity under oxidative stress. The C3H/AnL strain was found to be negative for the tlr4 gene mutation.
Conclusions: These data indicate that catalase deficiency plays an important role in the progression of renal injury in the ADR nephropathy model.

DOI： 10.1186/1471-2369-13-14

Suppression of Adiponectin by Aberrantly Glycosylated IgA1 in Glomerular Mesangial Cells In Vitro and In Vivo 査読

Tatsuyuki Inoue, Hitoshi Sugiyama, Masashi Kitagawa, Keiichi Takiue, Hiroshi Morinaga, Ayu Ogawa, Yoko Kikumoto, Shinji Kitamura, Yohei Maeshima, Hirofumi Makino

PLOS ONE 7 ( 3 ) e33965 2012年3月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：PUBLIC LIBRARY SCIENCE

The pathogenesis of IgA nephropathy (IgAN) may be associated with the mesangial deposition of aberrantly glycosylated IgA1. To identify mediators affected by aberrantly glycosylated IgA1 in cultured human mesangial cells (HMCs), we generated enzymatically modified desialylated and degalactosylated (deSial/deGal) IgA1. The state of deglycosylated IgA1 was confirmed by lectin binding to Helix aspersa (HAA) and Sambucus nigra (SNA). In the cytokine array analysis, 52 proteins were upregulated and 34 were downregulated in HMCs after stimulation with deSial/deGal IgA1. Among them, the secretion of adiponectin was suppressed in HMCs after stimulation with deSial/deGal IgA1. HMCs expressed mRNAs for adiponectin and its type 1 receptor, but not the type 2 receptor. Moreover, we revealed a downregulation of adiponectin expression in the glomeruli of renal biopsy specimens from patients with IgAN compared to those with lupus nephritis. We also demonstrated that aberrantly glycosylated IgA1 was deposited in the mesangium of patients with IgAN by dual staining of HAA and IgA. Moreover, the urinary HAA/SNA ratio of lectin binding was significantly higher in IgAN compared to other kidney diseases. Since adiponectin has anti-inflammatory effects, including the inhibition of adhesion molecules and cytokines, these data suggest that the local suppression of this adipokine by aberrantly glycosylated IgA1 could be involved in the regulation of glomerular inflammation and sclerosis in IgAN.

DOI： 10.1371/journal.pone.0033965

日本発PD療法のエビデンスを目指して多施設PD合同レジストリー前向きコホート研究によるエビデンス創出を目指して

杉山斉, 伊藤恭彦, 鶴屋和彦, 吉田寿子, 丸山弘樹, 後藤眞, 中山昌明, 森永裕士, 槇野博史, 松尾清一

腎と透析別冊腹膜透析2012 73 22 - 24 2012年

【腎臓症候群(第2版)下-その他の腎臓疾患を含めて-】維持透析患者にみられる病態栄養障害(MIA症候群)

森永裕士, 杉山斉

日本臨床腎臓症候群下 188 - 192 2012年

Icodextrin Increases Technique Survival Rate in Peritoneal Dialysis Patients with Diabetic Nephropathy by Improving Body Fluid Management: A Randomized Controlled Trial 査読

Yuji Takatori, Shigeru Akagi, Hitoshi Sugiyama, Junko Inoue, Shoichiro Kojo, Hiroshi Morinaga, Kazushi Nakao, Jun Wada, Hirofumi Makino

Clinical Journal of the American Society of Nephrology 6 ( 6 ) 1337 - 1344 2011年6月

Serum high-sensitivity cardiac troponin T is a significant biomarker of left-ventricular diastolic dysfunction in subjects with non-diabetic chronic kidney disease. 査読国際誌

Kitagawa M, Sugiyama H, Morinaga H, Inoue T, Takiue K, Kikumoto Y, Uchida HA, Kitamura S, Maeshima Y, Toh N, Nakamura K, Ito H, Makino H

Nephron extra 1 ( 1 ) 166 - 177 2011年1月

腹膜透析合同レジストリーとベースライン解析多施設共同前向きコホート研究

杉山斉, 伊藤恭彦, 鶴屋和彦, 吉田寿子, 丸山弘樹, 後藤眞, 中山昌明, 森永裕士, 槇野博史, 松尾清一

腎と透析別冊腹膜透析2011 71 251 - 252 2011年

Abnormalities of Glycogenes in Tonsillar Lymphocytes in IgA Nephropathy 査読

Tatsuyuki Inoue, Hitoshi Sugiyama, Masashi Kitagawa, Keiichi Takiue, Hiroshi Morinaga, Yoko Kikumoto, Yohei Maeshima, Kunihiro Fukushima, Kazunori Nishizaki, Hirofumi Akagi, Yoshiyuki Hiki, Hirofumi Makino

Recent Advances in Tonsils and Mucosal Barriers of the Upper Airways 71 - 74 2011年

Fabry disease exhibiting recurrent stroke and persistent inflammation

Yoko Kikumoto, Yasufumi Kai, Hiroshi Morinaga, Mutsunori Iga-Murahashi, Mikitaro Matsuyama, Takashi Sasaki, Hiroki Maruyama, Masaaki Shimotori, Hirofumi Makino, Hitoshi Sugiyama, Akihiko Okayama

Internal medicine 49 ( 20 ) 2247 - 2252 2010年10月

記述言語：英語掲載種別：研究論文（学術雑誌）

We describe two cases of Fabry disease in non-blood-related Japanese men, manifesting recurrent stroke even after the start of enzyme replacement therapy. Both exhibited chronic inflammation and ocular involvement with elevated levels of serum C reactive protein prior to the onset of stroke. We, therefore, suggest the association among persistent inflammation, ocular involvement and recurrent stroke in a certain subset of Fabry disease patients. Both cases received enzyme replacement therapy with no improvement in inflammatory signs or laboratory data. These cases suggest that Fabry disease should be considered in young patients with cryptogenic stroke or CNS manifestations and fever of unknown origin.

A case of immunotactoid glomerulopathy exhibiting nephrotic syndrome successfully treated with corticosteroids and antihypertensive therapy 査読

Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy 査読

Tatsuyuki Inoue, Hitoshi Sugiyama, Yoshiyuki Hiki, Keiichi Takiue, Hiroshi Morinaga, Masashi Kitagawa, Yohei Maeshima, Kunihiro Fukushima, Kazunori Nishizaki, Hirofumi Akagi, Yoshiki Narimatsu, Hisashi Narimatsu, Hirofumi Makino

Clinical Immunology 136 ( 3 ) 447 - 455 2010年9月

Sensitization to alloxan-induced diabetes and pancreatic cell apoptosis in acatalasemic mice 査読

Yoko Kikumoto, Hitoshi Sugiyama, Tatsuyuki Inoue, Hiroshi Morinaga, Keiichi Takiue, Masashi Kitagawa, Naomi Fukuoka, Mizuho Saeki, Yohei Maeshima, Da-Hong Wang, Keiki Ogino, Noriyoshi Masuoka, Hirofumi Makino

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1802 ( 2 ) 240 - 246 2010年2月

Masaru Kinomura, Yohei Maeshima, Ryo Kodera, Hiroshi Morinaga, Daisuke Saito, Kazushi Nakao, Hiroyuki Yanai, Kenei Sada, Hitoshi Sugiyama, Hirofumi Makino

Clinical and Experimental Nephrology 13 ( 4 ) 378 - 384 2009年8月

Unique microstructures and podocytic infolding in glomerular basement membrane associated with collagen diseases: a report of three cases 査読

Hitoshi Sugiyama, Mie Maruyama, Hiroshi Morinaga, Tatsuyuki Inoue, Kei-ichi Takiue, Yoko Kikumoto, Masaru Kinomura, Ken-ei Sada, Shigeru Akagi, Shinji Kitamura, Yohei Maeshima, Hirofumi Makino

CLINICAL AND EXPERIMENTAL NEPHROLOGY 12 ( 6 ) 450 - 454 2008年12月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：SPRINGER

Unique renal histopathological appearances, consisting of podocytic infolding and microstructures in the glomerular basement membrane (GBM) were identified in the renal biopsies from three patients with collagen diseases such as systemic lupus erythematosus (lupus nephritis, class II) and Sjogren's syndrome. In each case, the GBM contained microstructures, including microspheres and microtubular structures, accompanied by podocytic infolding into the GBM when examined by electron microscope. The size of the microstructures in the GBM ranged from 40 to 160 nm. Glomerular endothelial cells also seemed to be infolded in the GBM in a case with lupus nephritis. The response to glucocorticoid therapy was favorable in two cases. The cause of these morphological changes in the GBM might be associated with autoimmune disorders.

DOI： 10.1007/s10157-008-0098-6